Group 1 - The core point of the article is that Aikesaibo (SH 688719) held its 13th meeting of the 5th board of directors on October 24, 2025, to discuss granting restricted stock to incentive targets [1] - For the fiscal year 2024, Aikesaibo's revenue composition is as follows: 47.59% from new energy testing, 20.53% from general testing, 16.47% from smart distribution networks, 12.74% from high-end equipment, and 2.67% from other businesses [1] - As of the report date, Aikesaibo has a market capitalization of 4.4 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have generated $80 billion in overseas licensing this year, highlighting a hot secondary market in biomedicine, while the primary market faces fundraising challenges [1]